非雄激素合成代谢激素可预测衰弱风险:欧洲男性老龄化研究前瞻性数据
欧洲男性老龄化研究对8个中心3369名40至79岁社区男性随访4.3年,发现IGF-1、IGFBP-3和25OHD每升高1个标准差,衰弱表型恶化和衰弱指数升高的风险降低;DHEA-S仅在70岁以上男性中与衰弱表型恶化风险降低相关。
要点
- IGF-1每升高1个标准差,衰弱表型恶化OR为0.82,衰弱指数变化为-3.7%。
- IGFBP-3每升高1个标准差,衰弱表型恶化OR为0.84,衰弱指数变化为-4.2%。
- 25OHD每升高1个标准差,衰弱表型恶化OR为0.84,衰弱指数变化为-4.4%。
核心结论
- 这些纵向数据证实非雄激素合成代谢激素与衰弱状态变化之间存在关联。
- 需要干预性研究来确定因果关系并明确治疗意义。
研究设计与样本
- 欧洲男性老龄化研究是一项为期4.3年的前瞻性观察研究,纳入来自8个欧洲中心的3369名40至79岁社区居住男性。
- 衰弱状态采用衰弱表型(FP,n=2114)和衰弱指数(FI,n=2444)判定。
主要发现
- 在调整年龄、体质指数、中心和基线衰弱的模型中,IGF-1每升高1个标准差,衰弱表型恶化OR为0.82(0.73,0.93),衰弱指数变化为-3.7%(-6.0,-1.5)。
- IGFBP-3每升高1个标准差,衰弱表型恶化OR为0.84(0.75,0.95),衰弱指数变化为-4.2%(-6.4,-2.0)。
- 25OHD每升高1个标准差,衰弱表型恶化OR为0.84(0.75,0.95),衰弱指数变化为-4.4%(-6.7,-2.0)。
- 调整IGFBP-3后,IGF-1与衰弱指数的关联减弱。
- DHEA-S较高仅与70岁以上男性衰弱表型恶化风险降低相关,OR为0.57(0.35,0.92);PTH与衰弱状态变化无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Low levels of nonandrogenic anabolic hormones have been linked with frailty, but evidence is conflicting and prospective data are largely lacking. OBJECTIVE: To determine associations between nonandrogenic anabolic hormones and prospective changes in frailty status. DESIGN/SETTING: A 4.3-year prospective observational study of community-dwelling men participating in the European Male Ageing Study. PARTICIPANTS: Men (n = 3369) aged 40 to 79 years from eight European centers. MAIN OUTCOME MEASURES: Frailty status was determined using frailty phenotype (FP; n = 2114) and frailty index (FI; n = 2444). ANALYSIS: Regression models assessed relationships between baseline levels of insulinlike growth factor 1 (IGF-1), its binding protein 3 (IGFBP-3), dehydroepiandrosterone sulfate (DHEA-S), 25-hydroxyvitamin D (25OHD), and parathyroid hormone (PTH), with changes in frailty status (worsening or improving frailty). RESULTS: The risk of worsening FP and FI decreased with 1 standard deviation higher IGF-1, IGFBP-3, and 25OHD in models adjusted for age, body mass index, center, and baseline frailty [IGF-1: odds ratio (OR) for worsening FP, 0.82 (0.73, 0.93), percentage change in FI, -3.7% (-6.0, -1.5); IGFBP-3: 0.84 (0.75, 0.95), -4.2% (-6.4, -2.0); 25OHD: 0.84 (0.75, 0.95); -4.4%, (-6.7, -2.0)]. Relationships between IGF-1 and FI were attenuated after adjusting for IGFBP-3. Higher DHEA-S was associated with a lower risk of worsening FP only in men >70 years old [OR, 0.57 (0.35, 0.92)]. PTH was unrelated to change in frailty status. CONCLUSIONS: These longitudinal data confirm the associations between nonandrogenic anabolic hormones and the changes in frailty status. Interventional studies are needed to establish causality and determine therapeutic implications.
引用
- Swiecicka A, Lunt M, Ahern T, et al. Nonandrogenic Anabolic Hormones Predict Risk of Frailty: European Male Ageing Study Prospective Data. J Clin Endocrinol Metab. 2017. PMID: 28609827. doi:10.1210/jc.2017-00090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。